腮腺恶性肿瘤当代管理:最新综述
本综述通过PRISMA流程检索2019年8月至2024年8月的PubMed文献,最终纳入137篇,系统更新腮腺恶性肿瘤的诊疗证据。低级别肿瘤单纯手术局部控制不劣于手术加辅助放疗; elective颈清扫对高级别肿瘤有生存获益;多数肿瘤化疗耐药,免疫及靶向治疗在晚期患者中显示前景。
要点
- 低级别腮腺癌单纯手术局部控制不劣于手术联合辅助放疗。
- 选择性颈清扫对高级别腮腺癌有生存获益,低级别无获益。
- 多数腮腺癌化疗耐药,免疫及靶向治疗在晚期患者中显示前景。
核心结论
- 低级别腮腺癌单纯手术局部控制不劣于手术加辅助放疗。
- 选择性颈清扫对高级别腮腺癌有生存获益,对低级别无获益。
- 多数腮腺癌化疗耐药,辅助化疗生存获益有限且显著降低生活质量,应仅用于特定患者。
- 针对HER-2、TRK和雄激素受体的免疫及靶向治疗在晚期腮腺癌中显示前景。
研究设计与样本
- 检索PubMed,按PRISMA流程设计检索方案,纳入2019年8月1日至2024年8月1日发表的文献。
- 初检1614篇,最终纳入137篇;排除非英文文献、摘要及病例报告/系列。
主要发现
- 多数低级别腮腺癌研究显示单纯手术局部控制不劣于手术联合辅助放疗。
- 选择性颈清扫对高级别腮腺癌有生存获益,对低级别无获益。
- 多数腮腺癌对化疗耐药,辅助化疗生存获益有限且显著降低生活质量。
- 针对HER-2、TRK和雄激素受体的免疫及靶向治疗在晚期腮腺癌中显示有前景的结果。
临床怎么用
- 低级别腮腺癌可考虑单纯手术,避免不必要的辅助放疗。
- 高级别腮腺癌应评估选择性颈清扫以改善生存。
- 辅助化疗仅用于特定患者,因生存获益有限且显著降低生活质量。
- 晚期腮腺癌可检测HER-2、TRK和雄激素受体等标志物以指导靶向或免疫治疗。
局限性
- 未来需开展研究以强调针对这类罕见恶性肿瘤的个体化肿瘤治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To provide a systematic update on the contemporary management of malignancies of the parotid gland (MPG), focusing on evidence-based practices and emerging therapeutics. DATA SOURCES: PubMed literature search. REVIEW METHODS: A search protocol was designed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) process for articles published between August 1, 2019, and August 1, 2024. Primary exclusion criteria were non-English text, abstracts, and case reports/series. Secondary inclusion criteria were articles specific to MPG diagnosis, histology, outcomes, and management, including surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy. CONCLUSION: A total of 1614 articles were identified, and 137 articles were included in the final review. Most studies on low-grade MPG found that surgery alone was noninferior to surgery and adjuvant radiotherapy for local control. Elective neck dissection provided survival benefits for high-grade, but not low-grade, MPG. Most MPG are chemotherapy-resistant. Adjuvant chemotherapy provides limited survival benefits while significantly worsening quality of life and, thus, should be used only in select patients. Immunotherapy and targeted therapies for markers, including HER-2, TRK, and androgen receptors, have shown promising results in the treatment of advanced MPG. IMPLICATIONS FOR PRACTICE: Advances in the treatment of MPG have improved survival while minimizing treatment toxicity and improving quality of life. Future studies are needed to emphasize personalized oncologic treatment for patients with these rare malignancies.
引用
- Tang A, Helou V, Sridharan SS, et al. Contemporary Management of Malignancies of the Parotid Gland: A State-of-the-Art Review. Otolaryngol Head Neck Surg. 2026. PMID: 41696986. doi:10.1002/ohn.70170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。